A Trial of a Triple-Drug Treatment for Lymphatic Filariasis

Christopher L King, James Suamani, Nelly Sanuku, Yao-Chieh Cheng, Samson Satofan, Brooke Mancuso, Charles W Goss, Leanne J Robinson, Peter M Siba, Gary J Weil, James W Kazura, Christopher L King, James Suamani, Nelly Sanuku, Yao-Chieh Cheng, Samson Satofan, Brooke Mancuso, Charles W Goss, Leanne J Robinson, Peter M Siba, Gary J Weil, James W Kazura

Abstract

Background: The World Health Organization has targeted lymphatic filariasis for global elimination by 2020 with a strategy of mass drug administration. This trial tested whether a single dose of a three-drug regimen of ivermectin plus diethylcarbamazine plus albendazole results in a greater sustained clearance of microfilariae than a single dose of a two-drug regimen of diethylcarbamazine plus albendazole and is noninferior to the two-drug regimen administered once a year for 3 years.

Methods: In a randomized, controlled trial involving adults from Papua New Guinea with Wuchereria bancrofti microfilaremia, we assigned 182 participants to receive a single dose of the three-drug regimen (60 participants), a single dose of the two-drug regimen (61 participants), or the two-drug regimen once a year for 3 years (61 participants). Clearance of microfilariae from the blood was measured at 12, 24, and 36 months after trial initiation.

Results: The three-drug regimen cleared microfilaremia in 55 of 57 participants (96%) at 12 months, in 52 of 54 participants (96%) at 24 months, and in 55 of 57 participants (96%) at 36 months. A single dose of the two-drug regimen cleared microfilaremia in 18 of 56 participants (32%) at 12 months, in 31 of 55 participants (56%) at 24 months, and in 43 of 52 participants (83%) at 36 months (P=0.02 for the three-drug regimen vs. a single dose of the two-drug regimen at 36 months). The two-drug regimen administered once a year for 3 years cleared microfilaremia in 20 of 59 participants (34%) at 12 months, in 42 of 56 participants (75%) at 24 months, and in 51 of 52 participants (98%) at 36 months (P=0.004 for noninferiority of the three-drug regimen vs. the two-drug regimen administered once a year for 3 years at 36 months). Moderate adverse events were more common in the group that received the three-drug regimen than in the combined two-drug-regimen groups (27% vs. 5%, P<0.001). There were no serious adverse events.

Conclusions: The three-drug regimen induced clearance of microfilariae from the blood for 3 years in almost all participants who received the treatment and was superior to the two-drug regimen administered once and noninferior to the two-drug regimen administered once a year for 3 years. (Funded by the Bill and Melinda Gates Foundation; ClinicalTrials.gov number, NCT01975441 .).

Figures

Figure 1.. Enrollment and follow-up of participants…
Figure 1.. Enrollment and follow-up of participants in the treatment trial.
Figure 2.
Figure 2.
Percent of participants with complete Mf clearance at 12 and 24 months post- treatment with DEC/ALB x 1 (hatched bars), DEC/ALB x 2 (light bars), and IVM/DEC/ALB x 1 (dark solid bars). Mf clearance rates were significantly higher for the IVM/DEC/ALB x 1 group compared to the other two groups at both 12 and 24 months (***p

Figure 3.

Reductions in Mf counts at…

Figure 3.

Reductions in Mf counts at 12 and 24 months post-treatment. Note the log…

Figure 3.
Reductions in Mf counts at 12 and 24 months post-treatment. Note the log scale + 1 for Mf counts. A single dose of IVM/DEC/ALB was significantly more effective for reducing Mf counts than either of the two DEC/ALB treatments at 12 and 24 months, p
Comment in
Similar articles
Cited by
References
    1. Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet 2010;376:1175-85. - PubMed
    1. King J, Biswas G. Global programme to eliminate lymphatic filariasis: progress report, 2015. WHO Weekly Epidemiological Record 2016;91 441–60.
    1. Ramaiah KD, Ottesen EA. Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease. PLoS NTD 2014;8:e3319. - PMC - PubMed
    1. Bockarie MJ, Tisch DJ, Kastens W, et al. Mass treatment to eliminate filariasis in Papua New Guinea. NEJM 2002;347:1841-8. - PubMed
    1. Farid HA, Hammad RE, Hassan MM, Ramzy RM, El Setouhy M, Weil GJ. Effects of combined diethylcarbamazine and albendazole treatment of bancroftian filariasis on parasite uptake and development in Culex pipiens L. Am J Trop Med Hyg 2005;73:108-14. - PubMed
Show all 22 references
Publication types
MeSH terms
Associated data
Full text links [x]
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM
Figure 3.
Figure 3.
Reductions in Mf counts at 12 and 24 months post-treatment. Note the log scale + 1 for Mf counts. A single dose of IVM/DEC/ALB was significantly more effective for reducing Mf counts than either of the two DEC/ALB treatments at 12 and 24 months, p

References

    1. Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet 2010;376:1175-85.
    1. King J, Biswas G. Global programme to eliminate lymphatic filariasis: progress report, 2015. WHO Weekly Epidemiological Record 2016;91 441–60.
    1. Ramaiah KD, Ottesen EA. Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease. PLoS NTD 2014;8:e3319.
    1. Bockarie MJ, Tisch DJ, Kastens W, et al. Mass treatment to eliminate filariasis in Papua New Guinea. NEJM 2002;347:1841-8.
    1. Farid HA, Hammad RE, Hassan MM, Ramzy RM, El Setouhy M, Weil GJ. Effects of combined diethylcarbamazine and albendazole treatment of bancroftian filariasis on parasite uptake and development in Culex pipiens L. Am J Trop Med Hyg 2005;73:108-14.
    1. Ismail MM, Jayakody RL, Weil GJ, et al. Long-term efficacy of single-dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Trans Roy Soc Trop Med and Hyg 2001;95:332-5.
    1. Ismail MM, Jayakody RL, Weil GJ, et al. Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Trans Roy Soc Trop Med and Hyg 1998;92:94-7.
    1. Michael E, Malecela-Lazaro MN, Kazura JW. Epidemiological modelling for monitoring and evaluation of lymphatic filariasis control. Adv Parasitol 2007;65:191-237.
    1. Thomsen EK, Sanuku N, Baea M, et al. Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis. Clin Infect Dis 2016;62:334-41.
    1. Moulia-Pelat JP, Glaziou P, Nguyen LN, Chanteau S, Martin PM, Cartel JL. Long-term efficacy of single-dose treatment with 400 -1 of ivermectin in bancroftian filariasis: results at one year. Trop Med Parasitol 1993;44:333-4.
    1. Weil GJ, Jain DC, Santhanam S, et al. A monoclonal antibody-based enzyme immunoassay for detecting parasite antigenemia in bancroftian filariasis. J Inf Dis 1987;156:350-5.
    1. Weil GJ, Malane MS, Powers KG, Blair LS. Monoclonal antibodies to parasite antigens found in the serum of Dirofilaria immitis-infected dogs. J Immunol 1985;134:1185-91.
    1. Bockarie MJ, Tavul L, Ibam I, et al. Efficacy of single-dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. Am J Trop Med Hyg 2007;76:62-6.
    1. Snow LC, Bockarie MJ, Michael E. Transmission dynamics of lymphatic filariasis: vector- specific density dependence in the development of Wuchereria bancrofti infective larvae in mosquitoes. Med Vet Ent 2006;20:261-72.
    1. Erickson SM, Thomsen EK, Keven JB, et al. Mosquito-parasite interactions can shape filariasis transmission dynamics and impact elimination programs. PLoS NTD 2013;7:e2433.
    1. Hussein O, El Setouhy M, Ahmed ES, et al. Duplex Doppler sonographic assessment of the effects of diethylcarbamazine and albendazole therapy on adult filarial worms and adjacent host tissues in Bancroftian filariasis. Am J Trop Med Hyg 2004;71:471-7.
    1. Noroes J, Dreyer G, Santos A, Mendes VG, Medeiros Z, Addiss D. Assessment of the efficacy of diethylcarbamazine on adult Wuchereria bancrofti in vivo. Trans Roy Soc Trop Med and Hyg 1997;91:78-81.
    1. Helmy H, Weil GJ, Ellethy AS, Ahmed ES, Setouhy ME, Ramzy RM. Bancroftian filariasis: effect of repeated treatment with diethylcarbamazine and albendazole on microfilaraemia, antigenaemia and antifilarial antibodies. Trans Roy Soc Trop Med and Hyg 2006;100:656-62.
    1. Geary TG. Ivermectin 20 years on: maturation of a wonder drug. Trends Parasitol 2005;21:530-2.
    1. Horton J, Witt C, Ottesen EA, et al. An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis. Parasitology 2000;121 Suppl:S147-60.
    1. Irvine MA, Stolk WA, Smith ME, et al. Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study. The Lancet Infect Dis 2017;17:451-8.
    1. Hooper PJ, Chu BK, Mikhailov A, Ottesen EA, Bradley M. Assessing progress in reducing the at-risk population after 13 years of the global programme to eliminate lymphatic filariasis. PLoS NTD 2014;8:e3333.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅